Advancing the development and licensure of vaginal rings and innovative systemic methods for prevention of HIV infection in women

Funding Agency:
US Agency for International Development

USAID is committed to moving the microbicides field forward through continued development of promising and innovative HIV prevention products for women in high HIV incidence settings. For the purposes of this NFO the term “microbicides” should be considered as broadly referring to different forms of pre- and post-exposure prophylaxis. Applications may, and are encouraged to, address more than one objective, particularly through strategic public or private partnerships that provide synergy through unbiased collaboration for optimal product development across dosage forms and active ingredients.

  • Objective 1: Expedite activities required for licensure and market introduction of a dapivirine ring product and bridging opportunities to progress toward licensure of a nextgeneration ring product (e.g. 90 days or more). These should coordinate with and build upon past and other ongoing projects.
  • Objective 2: Support development and optimization of systemic microbicide or multipurpose prevention technologies (MPTs) (e.g. products that combine prevention of HIV with prevention of pregnancy). 

Deadline for Concept Papers: May 20, 2016

Agency Website

Amount Description

USAID expects to award two to four Cooperative Agreements under this NFO, one for Objective 1 and one to three awards for Objective 2. Subject to funding availability, USAID intends to provide $50,000,000 in total USAID funding over a 5 (five) year period, of which $25,000,000 is intended for Objective 1; and $25,000,000 for Objective 2. 

Funding Type





Engineering and Physical Sciences
International Opportunities
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

May 20, 2016